OMEICOS Therapeutics
OMEICOS Therapeutics is developing a novell molecule utilizing a new Mode of Action for the treatment and prevention of atrial fibrillation.
Funding reportedLast round: Series C
What company datasets say OMEICOS Therapeutics raised
Funding, as reported
Reported in all37.3Min the source's currency
Rounds6
Last roundSeries C
Last round dateNov 2018
Investors listed13
Founders and team
From OMEICOS Therapeutics's own website: 5 on the team.
- Karen UhlmannVice President Operations
- Peter SeilerHead of Treasury Vice President SMS GmbH
- Robert FischerCEO/Cso
- Edita BadeHead of Finance
- Bernhard KirschbaumChairman
Health Care in the same market
Startups like it
Is this your company?
Add your raise, your deck and your story, and put OMEICOS Therapeutics in front of investors. Or tell us what we have wrong.